Amneal PharmaceuticalsAMRX
About: Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Employees: 7,700
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
339% more call options, than puts
Call options by funds: $1.56M | Put options by funds: $355K
61% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 44
36% more capital invested
Capital invested by funds: $657M [Q1] → $891M (+$234M) [Q2]
17% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 30
10.43% more ownership
Funds ownership: 35.36% [Q1] → 45.79% (+10.43%) [Q2]
3% more funds holding
Funds holding: 175 [Q1] → 180 (+5) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Truist Securities Les Sulewski 60% 1-year accuracy 3 / 5 met price target | 42%upside $12 | Buy Maintained | 2 Oct 2024 |
JP Morgan Chris Schott 33% 1-year accuracy 3 / 9 met price target | 7%upside $9 | Neutral Upgraded | 6 Sept 2024 |
Barclays Balaji Prasad 38% 1-year accuracy 12 / 32 met price target | 19%upside $10 | Overweight Maintained | 13 Aug 2024 |
Truist Securities Les Sulewski 60% 1-year accuracy 3 / 5 met price target | 19%upside $10 | Buy Maintained | 12 Aug 2024 |
Financial journalist opinion
Based on 6 articles about AMRX published over the past 30 days
